A biosciences and pharmaceutical firm in Long Island, California, has been given the go ahead to carry out research on medical marijuana. KannaLife Sciences was given the approval by the National Institutes of Health.
The research will determine if the chemicals found in marijuana can be used to treat Chronic Traumatic Encephalopathy (CTE). CTE is a condition that afflicts individuals who have borne multiple head concussions. KannaLife co-founder told News 12 of the green light on Monday. The company is presently conducting pre-clinical trials and expects to file with the Food and Drug Administration in early 2015.
Meanwhile, the Florida Medical Association, citing risks to public health, said it opposes the state’s planned medical marijuana program known as Amendment 2. Previously, the physician’s organization had voiced its opposition to the language used in the amendment as the Florida Supreme Court considered the proposal to introduce it to the ballot. But when the Supreme Court voted in favor of it, the association shifted to a neutral stance as the other organizations such as Save Our Society From Drugs and the Florida Sheriff’s Association continued with the opposition.
But this is no longer the case after the doctors rejoined them again.
“Providing compassionate care to our patients is something we do everyday. We believe the untended consequences of Amendment 2 are serious and numerous enough for us to believe they constitute a public health risk for Floridians,” said Dr. Alan B. Pillersdorf, the president of the FMA on Monday.
Voters will head to the ballet in November to decide the fate of Amendment 2, which based on the current opinion polls, looks set for a smooth sailing. To register for a free 2-week subscription to ForexMinute Premium Plan, visit www.forexminute.com/newsletter.
To contact the reporter of this story; Jonathan Millet at firstname.lastname@example.org